Home › NDC Lookup › Ingredients › Alternaria Alternata › 22840-5600-05
Alternaria alternata .05 g/mL Solution, 5 mL — NDC 22840-5600-05 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Alternaria alternata .05 g/mL Solution, 5 mL — NDC 22840-5600-5 (Billing 22840-5600-05)

by Greer Laboratories, Inc. · 5 mL in 1 BOTTLE, DROPPER

This is a package of 5 mL of Alternaria alternata .05 g/mL Solution from Greer Laboratories, Inc., first listed with the FDA Sep 1981 and currently FDA-listed.

NDC 22840-5600-05
🏷️ FDA NDC (as labeled) 22840-5600-5 billing pads the package segment with a zero
This package
Contains5 mL Pack sizes3 compare ↓
Brand FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Oct 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 22840-5600-5 alone.

Record
FDA NDC Directory package listing · Non-standardized allergenic
Code segments
22840 labeler · 5600 product · 5 package
Package marketed since
Sep 15, 1981
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 2284056005 7
FDA record last changed
Oct 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 22840-5600-5
Product NDC 22840-5600
11-digit billing NDC 22840560005
Application # BLA101833
SPL Set ID 77436178-2956-6a77-e053-2a91aa0a873e
Established class (EPC) Non-Standardized Fungal Allergenic Extract
Physiologic effect Cell-mediated Immunity; Increased Histamine Release; Increased IgG Production
Chemical class Allergens; Fungal Proteins
DEA schedule Non-controlled
Marketing category BLA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 1981-09-15
Route INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS
Dosage form SOLUTION
Substance ALTERNARIA ALTERNATA
Why two NDCs? The FDA registers this code as 22840-5600-5 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 22840-5600-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 10 ml 50 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
22840-5600-02 22840-5600-2 Main listing 10 mL in 1 VIAL, MULTI-DOSE 1981-09-15 — Active
22840-5600-04 22840-5600-4 50 mL in 1 VIAL, MULTI-DOSE 1981-09-15 — Active
22840-5600-05 You're viewing this 5 mL in 1 BOTTLE, DROPPER 1981-09-15 — Active

You're viewing the smallest of 3 pack sizes for this product.

Pack size FAQ

What quantity is in this package?
This package contains 5 mL — 5 ml in 1 bottle, dropper.
How does this package differ from NDC 22840-5600-02?
Both are Alternaria alternata .05 g/mL Solution — the drug itself is identical. This page's package is the 5 mL one, while NDC 22840-5600-02 is the 10 ml package.
What NDC number is used to bill for this package of Alternaria alternata .05 g/mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Alternaria alternata .05 g/mL 22840-1602-02 Greer 10 ml — — FDA listed —
Alternaria alternata .05 g/mLthis 22840-5600-05 Greer 5 ml — — FDA listed —
About this product: this is a biologic. Biologics don't have small-molecule generics — competition comes from FDA-licensed biosimilars (shown above), not generics.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & biosimilar status

🏛️
1981
Listed with the FDA since
Sep 1981
📍
2026
Currently FDA-listed
45 years listed
🧬
·
Biosimilars
see Purple Book
🧬Biologic — competition comes from biosimilars

Biologics have no small-molecule generics; biosimilar competition is tracked in the FDA Purple Book.

Where does this data come from?
Patents and exclusivity from the FDA Purple Book (biologics), refreshed from public FDA data. Biosimilar launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 339NCG44TV
    Phenol is a chemical compound derived from coal tar or petroleum. It serves as a preservative and antimicrobial agent in medicines, helping prevent bacterial and fungal growth to keep the product stable and safe during storage.
  • UNII 8MDF5V39QO
    A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerGreer Laboratories, Inc.
FDA applicationBLA101833 (BLA)
Labeler code22840
First marketedSep 1981
Product typeNon-standardized Allergenic
Portfolio1,328 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 168 words ▾

WARNING THIS ALLERGENIC PRODUCT IS INTENDED FOR USE BY PHYSICIANS WHO ARE EXPERIENCED IN THE ADMINISTRATION OF ALLERGENIC EXTRACTS AND THE EMERGENCY CARE OF ANAPHYLAXIS, OR FOR USE UNDER THE GUIDANCE OF AN ALLERGY SPECIALIST. ALLERGENIC EXTRACTS MAY CAUSE SEVERE OR FATAL ANAPHYLAXIS IN EXTREMELY SENSITIVE PATIENTS. THE INITIAL DOSE MUST BE BASED ON SKIN TESTING AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THIS INSERT.

PATIENTS SHOULD BE INSTRUCTED TO RECOGNIZE ADVERSE REACTION SYMPTOMS AND CAUTIONED TO CONTACT THE PHYSICIAN'S OFFICE IF REACTION SYMPTOMS OCCUR. IN CERTAIN INDIVIDUALS, THESE REACTIONS COULD BE FATAL. PATIENTS SHOULD BE OBSERVED FOR AT LEAST 20 MINUTES FOLLOWING TREATMENT.

EMERGENCY MEASURES, AS WELL AS PERSONNEL TRAINED IN THEIR USE, SHOULD BE IMMEDIATELY AVAILABLE IN THE EVENT OF A LIFE‑ THREATENING REACTION. PATIENTS BEING SWITCHED FROM ONE LOT OF EXTRACT TO ANOTHER FROM THE SAME MANUFACTURER SHOULD HAVE THEIR DOSE REDUCED BY 75%. THIS PRODUCT SHOULD NOT BE INJECTED INTRAVENOUSLY.

REFER ALSO TO THE WARNINGS, PRECAUTIONS, ADVERSE REACTIONS AND OVERDOSAGE SECTION BELOW.

🎯 Indications and Usage 112 words ▾

Allergenic Extracts are indicated for the diagnosis and treatment of patients with immediate hypersensitivity allergy to the respective allergens, inhaled, ingested or otherwise introduced into contact with sensitive tissues. The diagnosis of IgE‑mediated allergy may be established by the allergy history, clinical evaluation, and skin test reactivity. (4,7,11) Immunotherapy with Allergenic Extracts is indicated when testing and patient history have identified the offending allergens and when it is not possible or practical to avoid these allergens.

(12‑14) Food extracts have not been proven effective in immunotherapy. The use of Allergenic Extracts for the above purposes should be made only by physicians with special familiarity and knowledge of allergy. (See DOSAGE AND ADMINISTRATION)

⏱️ Dosage and Administration ~3 min read ▾

1. DIAGNOSTIC TESTING For the patient with a suspected diagnosis of allergy to more than one antigen, initial skin testing should include the individual extracts. If a screening skin test with a mixture is used, a positive response should be followed by testing with the individual extracts to determine the degree of sensitivity to each and to guide in the selection of extracts and their concentration for immunotherapy if indicated.

However, because a negative skin test with a mixture may not be indicative of the absence of allergy to one or more of the components due to their dilution, testing with individual extracts is more precise. False negative responses may occur if serum levels of antihistamines remain from prior medication administration (see CONTRAINDICATIONS). The use of a positive control is especially recommended for patients on prior medications which may decrease the histamine skin test response.

Scratch or Prick‑puncture Skin Testing: Allergenic Extract concentrates may be used for scratch or prick‑puncture testing or scratch tests in 50% glycerin, 1:20 w/v or strongest available strength in 5 mL vials may be used. Prick‑puncture tests with concentrated extracts in patients highly sensitive to the specific antigen should yield distinctive wheals with diameters of greater than 5 mm and with much larger erythema reactions. Glycerinated histamine phosphate 5 mg/mL (1.8 mg/mL histamine base) or aqueous histamine phosphate 2.75 mg/mL (1 mg/mL histamine base; 1:1,000 W/V) may be used as a positive control.

Intradermal Skin Testing: Extract for intradermal testing must be prepared by diluting the stock concentrate injection vials with sterile diluent (use normal or buffered saline, or normal saline with human serum albumin) or the appropriate dilutions may be purchased. a. Patients with a negative scratch or prick‑puncture test: Patients who do not react to a scratch or prick‑puncture test should be tested intradermally, using a 26 or 27 gauge 1/4 inch needle, with 0.02 to 0.05 mL of an appropriate extract dilution from 1/100 to 1/1000 of the concentrate.

A negative test should be followed by a repeat test using a higher concentration until significant wheal and flare reaction sizes are attained or until the responses remain negative. As a negative control use the diluent or, in the case of extracts in 50% glycerin, use 0.5% to 1% glycerosaline solution. As a positive control, use glycerinated histamine phosphate diluted to 0.5 mg/mL (0.18 mg/mL histamine base) or aqueous histamine phosphate 0.275 mg/mL (0.1 mg/mL histamine base). b.

Patients tested only by the intradermal method: Since highly reactive individuals may react intracutaneously at 1:1 million or even 1:10 million dilutions, any intradermal injection should be preceded by a puncture test and the dose adjusted accordingly. Other patients suspected of being moderately allergic should be tested with 0.02 to 0.05 mL of an appropriate extract dilution on the order of 1/10,000 to 1/100,000 of the concentrate. A negative test should be followed by repeat tests using progressively stronger ten‑fold concentrations until significant wheal and flare reaction sizes are attained, or until skin test responses with the higher concentrations remain negative.

As a negative control, use the diluent or, in the case of extracts in 50% glycerin, use 0.5% to 1% glycerosaline solution. As a positive control, use glycerinated histamine phosphate diluted to 0.5 mg/mL (0.18 mg/mL histamine base) or aqueous histamine phosphate 0.275 mg/mL (0.1 mg/mL histamine base). Skin tests are graded in terms of the wheal and erythema response noted at 15 to 20 minutes, and compared to the appropriate controls.

Wheal and erythema sizes may be recorded by actual measurement. 2. IMMUNOTHERAPY Immunotherapy is administered by subcutaneous injection.

Dosage of Allergenic Extracts is individualized according to the patient's sensitivity, the clinical response, and tolerance to the extract administered… [Excerpted — this section continues on DailyMed.]

⛔ Contraindications 133 words ▾

There are no known absolute contraindications to the use of Allergenic Extracts for immunotherapy. Immunotherapy with specific antigens should not be done in those individuals who do not exhibit skin test or clinical sensitivity to the particular antigens. (See below under WARNINGS and PRECAUTIONS) Allergenic extract injections should not be administered in the presence of diseases characterized by a bleeding diathesis.

Children with nephrotic syndrome require careful consideration and probably should not receive injection therapy because a variety of seemingly unrelated events, such as immunization, can cause an exacerbation of their nephrotic disease. General contraindications include: EXTREME SENSITIVITY TO THE SPECIFIC ALLERGEN ‑ Determined from previous anaphylaxis following exposure. AUTOIMMUNE DISEASE ‑ Individuals with autoimmune disease may be at risk, due to the possibility of routine immunizations exacerbating symptoms of the underlying disease.

⚠️ Warnings ~1 min read ▾

Concentrated extracts must be diluted with a sterile diluent prior to first use on a patient for treatment or intradermal testing. Allergenic Extracts are manufactured to assure high potency and have the ability during skin testing and immunotherapy to cause serious local and systemic reactions including death in sensitive patients. Most reactions occur within 20 minutes after injection, (15) but may occur later.

(16) To minimize the potential for local or systemic reactions, the relative sensitivity of the patient must be assessed from the allergic history and from clinical observations. Patients should be informed of these risks prior to skin testing and immunotherapy (see PRECAUTIONS and ADVERSE REACTIONS below). Allergenic Extract immunotherapy doses should be lowered or temporarily withheld from patients if any of the following conditions exist: (1) severe symptoms of rhinitis and/or asthma (2) infection or flu accompanied by fever (3) exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection (4) evidence of a local or systemic reaction to the preceding extract injection during a course of immunotherapy The dosage must be reduced when modifying dosages or components in a mixture or an individual prescription, or when starting a patient on fresh extract, even though the labeled strength of the old and new vials may be the same.

This reduction in dosage may be necessary due to the older vial losing potency during storage, or due to different sensitivities to different components. The amount of new extract given should not exceed 25% of the last dose given from the old vial, assuming both extracts contain comparable amounts of allergen. Any evidence of a local or generalized reaction requires a reduction in dosage during the initial stages of immunotherapy, as well as during maintenance therapy.

🤒 Adverse Reactions ~1 min read ▾

Adverse systemic reactions may occur within minutes upon use of an Allergenic Extract to which a person has specific sensitivity. These reactions consist primarily of allergic symptoms such as generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. Less commonly, nausea, emesis, abdominal cramps, diarrhea and uterine contractions may occur.

Severe reactions may cause shock and loss of consciousness. Fatalities have occurred rarely. (8,22,23) These systemic reactions occur with varying frequency in different clinics and are usually less than 1%.

To some extent, the reaction rate is related to the type and dose of administered extract and to the sensitivity of the patient. In general, immunotherapy with Allergenic Extracts is considered to be safe. (24) Despite all precautions, occasional reactions are unavoidable.

Adverse systemic reactions should be treated as follows: A. A tourniquet should be immediately applied to the extremity above the site of injection. Release the tourniquet every few minutes for a few seconds.

B. Epinephrine 1:1000 should be injected immediately in the opposite arm in amounts of 0.3 to 0.5 mL and 0.2 mL epinephrine should be administered at the site of injection. For children below the age of 6 years, adjust the dosage of epinephrine to 0.005 mL per pound of body weight per dose.

Repeat epinephrine dosage in 15 minutes if necessary and if symptoms persist. C. Adverse reactions not responding to epinephrine therapy may require the use of parenteral bronchodilators, vasopressors, oxygen, or volume replacement therapy.

Local reactions consisting of erythema, itching, swelling, tenderness and sometimes pain may occur at the injection site. These reactions may appear within a few minutes to hours and persist for several days. Local cold applications and oral antihistamines may be effective treatment.

For marked and prolonged local reactions, steroids may be helpful.

🆘 Overdosage 94 words ▾

Systemic reactions are uncommon after injection, but if the patient receives more extract than can be tolerated at that particular time and begins to experience immediate hypersensitivity anaphylaxis, the procedures listed under ADVERSE REACTIONS should be instituted. Overdosage may occur because of an error in the volume of extract injected, or an incorrect dilution injected, or because the patient may be exposed to airborne or environmental antigens simultaneously with injection of the same antigens. In the event of a systemic reaction occurring, the dosage schedule should be carefully adjusted as outlined above under WARNINGS.

🧬 Clinical Pharmacology ~1 min read ▾

The allergic reaction is dependent upon the presence of antigen‑specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies on mast cells and basophils sensitizes these cells and, upon interaction with the appropriate allergen, histamine and other mediators are released. IgE antibody has been shown to correlate with atopic diseases such as allergic rhinitis and allergic asthma.

(1‑4) In the skin these mediators are responsible for the characteristic wheal and flare (erythema) reactions upon Allergenic Extract skin testing in persons with the specific allergies. (3‑7) Specific immunotherapy with Allergenic Extracts as employed for over 45 years is helpful in reducing symptoms associated with exposure to the offending allergens. A summary of effectiveness by the Panel on Review of Allergenic Extracts, an advisory committee to the U.S.

Food and Drug Administration, has been published. (8) Several mechanisms have been proposed to explain the effectiveness of immunotherapy: an increase in antigen‑specific IgG antibodies is frequently associated with clinical effectiveness, although correlation is not consistent in all studies; there is a decrease in specific IgE; and IgE production is suppressed during periods of seasonal or high exposure to the antigen. (9) Other changes following immunotherapy have been noted including development of auto‑anti‑idiotypic antibodies; a decrease in blood basophil sensitivity to allergen; a decrease in lymphokine production and lymphocyte proliferation by cells exposed to allergen; and development of allergen‑specific suppressor cells.

(10) The complete mechanisms of immunotherapy are not known and remain the subject of investigation.

📦 How Supplied / Storage and Handling 63 words ▾

Stock concentrate extracts containing up to 40,000 PNU/mL, or 1:10 W/V or other dilutions as requested by the physician are supplied in 5, 10, 30 and 50 mL in aqueous or 50% glycerin buffered saline. House dust extract is supplied in a 1:1 W/V concentrate, or a maximum of 10,000 PNU/mL. Extracts are also supplied in dropper vials for scratch or prick testing.

📦 Storage and Handling 87 words ▾

Allergenic Extracts should be stored at 2‑8°C and kept at this temperature range during office use. Refer to vial labels for expiration dates. Diluted extracts are inherently less stable than concentrates.

Dilutions of glycerinated extracts which result in glycerin below 50% are also less stable. The more dilute extracts in aqueous diluents should be replenished daily. Potency of a particular dilution can be checked by skin test in comparison to a fresh dilution of the extract on an individual known to be allergic to the specific antigen.

📋 Description ~1 min read ▾

Allergenic Extracts are supplied as a sterile solution for intracutaneous or subcutaneous administration. Concentrates contain the soluble extractants of the source material with 0.5% sodium chloride and 0.54% sodium bicarbonate at a pH of 6.8 to 8.4 as aqueous extracts in water for injection or in 50% glycerin. Aqueous extracts contain 0.4% phenol as a preservative and 50% glycerinated extracts contain 0.2% phenol.

Diluted aqueous extracts contain Buffered Saline with 0.5% sodium chloride, 0.04% potassium phosphate, 0.11% sodium phosphate heptahydrate, and 0.4% phenol in water for injection. Source materials for these extracts are as follows: Pollens are collected from the respective grasses, weeds, trees, shrubs, cultured plants and flowers. Mold extracts are produced from pure culture mycelial mats.

Rusts and smuts are obtained from natural growths. Epidermal extracts are produced from the hide, hair, or feathers containing the natural dander, or from separated dander. Insects are the whole body insects.

House dust is made from various dusts ordinarily found in the home with the extract dialyzed to remove low‑molecular weight irritants and concentrated to an extraction ratio of 1:1. Food extracts are prepared from the edible portions of the respective foods, obtained fresh if possible. Certain diagnostic food extracts contain 0.1% sodium formaldehyde sulfoxylate as an antioxidant.

Other miscellaneous inhalants involved in respiratory allergy are obtained in the naturally occurring form to which a patient may be exposed. Extracts are labeled either by weight‑to‑volume (w/v) based on the weight of the source material to the volume of the extracting fluid, or in protein nitrogen units (PNU) based on assay with one PNU representing 0.00001 mg of protein nitrogen.

⚠️ Precautions ~3 min read ▾

GENERAL: Not for intravenous use! Systemic allergic reactions may occur as a result of immunotherapy. The risk can be minimized by adherence to a careful injection schedule, which starts with a low concentration of extract and is increased slowly.

Because of the danger of serious reactions, caution is needed in testing exquisitely sensitive patients, particularly with potent allergens, e.g., peanut, cottonseed, and flaxseed. (8) Such extracts should be appropriately diluted before use. The physician must be prepared to treat anaphylaxis should it occur and have the necessary drugs and equipment on hand to do so.

(17‑18) Extracts should not be administered by the patient or other individuals who are not prepared to treat anaphylaxis should it occur. Patients receiving Allergenic Extracts should be kept under observation a minimum of twenty (20) minutes so that any adverse reaction can be observed and properly handled. (15) This time should be extended for high‑risk patients such as those with unstable asthma or those suffering an exacerbation of their symptoms.

Patients receiving beta blockers may not be responsive to beta adrenergic drugs used to treat anaphylaxis. The risks of anaphylaxis in these patients should be carefully weighed against the benefits of immunotherapy. Check the lot number and dosage schedule of the patient to verify correctness of a prescription number, a vial number, or strength.

Only after this verification has been made should an injection be given. A separate sterile needle and syringe should be used for each patient to prevent transmission of hepatitis or other infectious agents. INFORMATION FOR PATIENTS: Most serious reactions following the administration of Allergenic Extracts occur within 20 minutes; the patient should remain under observation for this period of time or longer if instructed by the physician.

The size of any local reaction should be recorded, because increasingly large local reactions may precede a subsequent systemic reaction with increasing dosage. The patient should be instructed to report any unusual reactions. In particular, this includes unusual swelling and/or tenderness at the injection site, or reactions such as rhinorrhea, sneezing, coughing, wheezing, shortness of breath, nausea, dizziness, or faintness.

Reactions may occur some time after leaving the physician's office, in which case medical attention should be sought immediately. DRUG INTERACTIONS: Skin test diagnosis with Allergenic Extracts is contraindicated within 24 hours after the last dose of most antihistamines, within 48 hours after the last dose of terfenadine, and within 3 weeks or longer after the last dose of astemizole. These products suppress histamine skin test reactions and could mask a positive response.

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: There is no evidence of carcinogenicity, mutagenesis or impairment of fertility in humans from Allergenic Extracts. No long‑term studies in animals have been performed to evaluate carcinogenic potential. PREGNANCY: PREGNANCY CATEGORY C ‑ Animal reproduction studies have not been conducted with Allergenic Extracts.

It is also not known whether Allergenic Extracts can cause fetal harm when administered to a pregnant woman or whether they can affect reproduction capacity. Allergenic Extracts should be given to a pregnant woman only if clearly needed. There is no evidence of adverse effects of Allergenic Extracts on the fetus.

(8) Studies have not been performed in animals to determine whether extracts affect fertility in males or females, have teratogenic potential, or have other adverse effects on the fetus. Caution should be exercised in testing or treating pregnant females because a systemic reaction may cause an abortion as a result of uterine muscle contractions. LABOR AND DELIVERY: There is no known information of adverse effects during labor and delivery.

NURSING MOTHERS: It is not known whether this product is excreted in human milk. Because m… [Excerpted — this section continues on DailyMed.]

📚 References ~2 min read ▾

Lichtenstein LM, Ishizaka K, Norman PS, et al. IgE antibody measurements in ragweed hayfever: relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:474.

Elgefors B, Julin A, Johansson SGO. Immunoglobulin E in bronchial asthma. Acta Allergol 1974;29:327.

Norman PS. The clinical significance of IgE. Hosp Pract 1975;10:41‑49.

Bryant DA, Burns MW, Lazarus L. The correlation between skin tests, bronchial provocation tests and the serum level of IgE specific for common allergens in patients with asthma. Clin Allergy 1975;5:145.

Loeffler JA, Cawley LP, Moeder M. Serum IgE levels: correlation with skin test sensitivity. Ann Allergy 1973;31:331.

Pepys J. Skin tests in diagnosis. In Gell PGH, Coombs RRA, Lachman PJ, eds.

Clinical aspects of Immunology. Oxford: Blackwell Scientific Publications, 1975. Burrows B, et al.

Respiratory disorders and allergy skin test reactions. Ann Allergy 1976;84:134. Implementation of Efficacy Review, Allergenic Extracts.

Federal Register 1985;50:3082‑3288 Levy DA, Lichenstein LM, Goldstein EO, Ishizaka K. Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest 1973;50:360.

Gurka G, Rocklin R. Immunologic responses during allergen-specific immunotherapy for respiratory allergy. Ann Allergy 1988;61:239-43.

Zeiss CR Jr. Patient evaluation. In: Allergy and Clinical Immunology, Locky RF, ed.

Garden City, N.Y.: Medical Examination Publishing 1976:616. Frankland AW, Augustin R. Prophylaxis of summer hay‑fever and asthma: a controlled trial comparing crude grass‑pollen extracts with the isolated main protein component.

Lancet 1954;1:1055. Frankland AW, Augustin R. Grass pollen antigens effective in treatment.

Clin Sci 1962;23:95. Rohr AS, Marshall NA, Saxon A: Successful immunotherapy for Triatoma protracta‑induced anaphylaxis. J Allergy Clin Immunol 1984;73:369‑75.

Executive Committee, American Academy of Allergy and Immunology. The waiting period after allergen skin testing and immunotherapy (Position statement). J Allergy Clin Immunol 1990;85:526‑7.

Greenberg MA, Kaufman CR, Gonzalez GE, Rosenblatt CD, Smith LJ, Summers RJ. Late and immediate systemic‑allergic reactions to inhalant allergen immunotherapy. J Allergy Clin Immunol 1986;77:865‑70.

Ouellette JJ. Emergency management of the allergic reactions. Modern Medicine 1975;99.

Anderson JA, et al. Personnel and equipment to treat systemic reactions caused by immunotherapy with allergenic extracts. J Allergy Clin Immunol 1986;77:271‑3.

Sadan N, Rhyne MB, Mellits ED, et al. Immunotherapy of pollenosis in children: investigation of the immunologic basis of clinical improvement. N Eng J Med 1969;280:623.

Johnstone DE. Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 1961;27:39.

VanAsperin PP, Kemp AS, Mellis CM. Skin test reactivity and clinical allergen sensitivity in infancy. J Allergy Clin Immunol 1984;73:381‑6.

Committee on Safety of Medicine. Desensitizing vaccines. Br Med J 1986;293:948.

Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987;79:660‑77.

Norman PS, Van Metre TE Jr. The safety of allergenic immunotherapy. J Allergy Clin Immunol 1990;85:522‑5.

📄 Package Label / Principal Display Panel 8 words ▾

1600-2_Alternaria alternata_20000-pnu 1628-1_Aspergillus niger_1000-wv 5610-4_Candida albicans_20-wv 9641-5_Fusarium Mix_40-wv

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Alternaria alternata — the ingredient across all brands.

Top reported reactions

Diarrhoea7
Decreased Appetite6
Pain5
Abdominal Pain4
Headache4
Malaise4
Vomiting4

Age at onset

Adult2

Reporter sex

45 reports
Male · 23%
Female · 77%

Serious outcomes

Hospitalization10
Disabling7
Life-threatening3
Death1
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Greer Laboratories, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 10 ml (22840-5600-02), 50 ml (22840-5600-04). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Greer Laboratories, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.